中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.025 seconds)

    Classification and Actionability Indices for Cancer
    1.
    发明申请
    Classification and Actionability Indices for Cancer 审中-公开
    癌症分类和可行动性指标

    公开(公告)号：US20150080239A1

    公开(公告)日：2015-03-19

    申请号：US14212717

    申请日：2014-03-14

    Applicant: LIFE TECHNOLOGIES CORPORATION

    Inventor： Daniel RHODES ,  Seth SADIS

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

    Abstract: The disclosure provides compositions, kits, and methods for detecting a plurality of genes and associated variants in a sample from a subject with cancer. The compositions, kits, and methods include a set of oligonucleotides, typically primers and/or probes that can hybridize to identify a gene variant. The methods disclosed herein provide for a mutation status of a tumor to be determined and subsequently associated with a report comprising an actionable treatment recommendation.

    Abstract translation: 本公开提供了用于检测来自患有癌症的受试者的样品中的多种基因和相关变体的组合物，试剂盒和方法。 组合物，试剂盒和方法包括一组寡核苷酸，通常可以杂交以鉴定基因变体的引物和/或探针。 本文公开的方法提供待确定的肿瘤的突变状态，并随后与包含可行动治疗推荐的报告相关联。

    Classification and Actionability Indices for Lung Cancer
    4.
    发明申请
    Classification and Actionability Indices for Lung Cancer 审中-公开
    肺癌分类及可行性指标

    公开(公告)号：US20160265065A1

    公开(公告)日：2016-09-15

    申请号：US15068011

    申请日：2016-03-11

    Applicant: LIFE TECHNOLOGIES CORPORATION

    Inventor： Santhoshi BANDLA ,  Douglas ROSS ,  Seth SADIS ,  Peter WYNGAARD

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

    Abstract: The disclosure provides compositions, kits, and methods for detecting a plurality of genes and associated variants in a sample from a subject with lung cancer. The compositions, kits, and methods include a set of oligonucleotides, typically primers and/or probes that can hybridize to identify a gene variant. The methods disclosed herein provide for a mutation status of a tumor to be determined and subsequently associated with an actionable treatment recommendation.

    Abstract translation: 本公开提供了用于检测来自患有肺癌的受试者的样品中的多种基因和相关变体的组合物，试剂盒和方法。 组合物，试剂盒和方法包括一组寡核苷酸，通常可以杂交以鉴定基因变体的引物和/或探针。 本文公开的方法提供待确定的肿瘤的突变状态，并随后与可行动治疗推荐相关联。

    METHODS FOR PARTNER AGNOSTIC GENE FUSION DETECTION
    5.
    发明申请
    METHODS FOR PARTNER AGNOSTIC GENE FUSION DETECTION 审中-公开

    公开(公告)号：US20200318175A1

    公开(公告)日：2020-10-08

    申请号：US16825238

    申请日：2020-03-20

    Applicant: LIFE TECHNOLOGIES CORPORATION

    Inventor： Rajesh GOTTIMUKKALA ,  Amir MARCOVITZ ,  Jeoffrey SCHAGEMAN ,  Varun BAGAI ,  Jian GU ,  James VEITCH ,  Kelli BRAMLETT ,  Scott MYRAND ,  Fiona HYLAND ,  Seth SADIS ,  Paul WILLIAMS

    IPC: C12Q1/6851 ,  G06F17/18 ,  G16B25/10

    Abstract: A method for detecting a gene fusion includes amplifying a nucleic acid sample in the presence of primer pool to produce a plurality of amplicons. The primer pool includes primers targeting a plurality of exon-exon junctions of a driver gene. The amplicons correspond to the exon-exon junctions. The amplicons are sequenced and aligned to a reference sequence. The number of reads corresponding to each amplicon is normalized to give a normalized read count. A baseline correction is applied to the normalized read counts for the amplicons to form corrected read counts. A binary segmentation score is calculated for each corrected read count. A predicted breakpoint for the gene fusion is determined based on the amplicon index corresponding to the maximum absolute binary segmentation score. Gene fusion events may be detected in a partner agnostic manner, i.e. without prior knowledge of the specific fusion partner genes or specific breakpoint information.

    PROGNOSTIC ASSAY FOR SQUAMOUS CELL LUNG CARCINOMA
    10.
    发明申请
    PROGNOSTIC ASSAY FOR SQUAMOUS CELL LUNG CARCINOMA 审中-公开
    慢性细胞肺癌的预后测定

    公开(公告)号：US20140357573A1

    公开(公告)日：2014-12-04

    申请号：US14210124

    申请日：2014-03-13

    Applicant: LIFE TECHNOLOGIES CORPORATION

    Inventor： Seth SADIS ,  Paul Williams

    IPC: C12Q1/68

    Abstract: Methods for predicting clinical outcome for a human subject diagnosed with squamous cell lung carcinoma using a panel of molecular markers that includes CDKN2A and CCND1. The markers are related to the subject's increased likelihood of a negative clinical outcome.

    Abstract translation: 使用包括CDKN2A和CCND1在内的一组分子标记物预测诊断为鳞状细胞肺癌的人类受试者的临床结果的方法。 标记与受试者增加阴性临床结果的可能性有关。

Patent Agency Ranking